Last reviewed · How we verify
PF-06863135 + lenalidomide (pf-06863135-lenalidomide)
PF-06863135 + lenalidomide (generic name: pf-06863135-lenalidomide) is a small molecule + immunomodulatory drug drug developed by Pfizer. It is currently FDA-approved for Relapsed or refractory multiple myeloma in combination with dexamethasone, Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab, Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib.
PF-06863135 (elranatamab) is being studied in combination with lenalidomide for the treatment of multiple myeloma, including newly diagnosed multiple myeloma that is transplant ineligible. The combination of elranatamab and lenalidomide is being investigated in a clinical trial (NCT05623020) sponsored by Pfizer.
At a glance
| Generic name | pf-06863135-lenalidomide |
|---|---|
| Sponsor | Pfizer |
| Drug class | small molecule + immunomodulatory drug |
| Target | unknown |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| Annual revenue | 2951 |
Approved indications
- Relapsed or refractory multiple myeloma in combination with dexamethasone
- Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab
- Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib
- Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab
- Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab
- Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib
- Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib
- Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide
- Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide
- Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135
- Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib
- Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib
- Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib
- Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab
- Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab
- Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab
- Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib
- Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib
- Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab
- Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab
Common side effects
Drug interactions
- PF-06863135
- PF-06863135
- Lenalidomide
- Lenalidomide
- Lenalidomide
- Lenalidomide
- Lenalidomide
- Lenalidomide
- Lenalidomide
- Lenalidomide
- Lenalidomide
- Lenalidomide
Key clinical trials
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments (PHASE3)
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) (PHASE3)
- A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant or Who Will Not Receive a Transplant as Initial Therapy (PHASE3)
- MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma (PHASE2)
- Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma (PHASE2)
- Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (PHASE3)
- ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma (PHASE2)
- PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-06863135 + lenalidomide CI brief — competitive landscape report
- PF-06863135 + lenalidomide updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about PF-06863135 + lenalidomide
What is PF-06863135 + lenalidomide?
PF-06863135 + lenalidomide (pf-06863135-lenalidomide) is a small molecule + immunomodulatory drug drug developed by Pfizer, indicated for Relapsed or refractory multiple myeloma in combination with dexamethasone, Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab, Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib.
What is PF-06863135 + lenalidomide used for?
PF-06863135 + lenalidomide is indicated for Relapsed or refractory multiple myeloma in combination with dexamethasone, Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab, Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib, Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab, Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab.
Who makes PF-06863135 + lenalidomide?
PF-06863135 + lenalidomide is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).
What is the generic name of PF-06863135 + lenalidomide?
pf-06863135-lenalidomide is the generic (nonproprietary) name of PF-06863135 + lenalidomide.
What drug class is PF-06863135 + lenalidomide in?
PF-06863135 + lenalidomide belongs to the small molecule + immunomodulatory drug class. See all small molecule + immunomodulatory drug drugs at /class/small-molecule-immunomodulatory-drug.
What development phase is PF-06863135 + lenalidomide in?
PF-06863135 + lenalidomide is FDA-approved (marketed).
What is PF-06863135 + lenalidomide's annual revenue?
PF-06863135 + lenalidomide generated approximately $0.0B in annual revenue.
What does PF-06863135 + lenalidomide target?
PF-06863135 + lenalidomide targets unknown and is a small molecule + immunomodulatory drug.
Related
- Drug class: All small molecule + immunomodulatory drug drugs
- Target: All drugs targeting unknown
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Relapsed or refractory multiple myeloma in combination with dexamethasone
- Indication: Drugs for Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab
- Indication: Drugs for Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing